CIFR
Cipher Mining Inc.
There isn't enough reported data to score CIFR yet.
CNS
Cohen & Steers, Inc.
CNS's fundamentals are mixed: revenue grew 8.6%, but its operating margin fell 1 points to 32%. At 22x earnings, it's trading below its usual 25x. Analysts expect earnings growth.
CIFR Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| N/A | |
| N/A |
CIFR's revenue and profitability are currently weak. Free cash flow and net leverage aren't meaningful measures for financial services companies like CIFR.
CNS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
CNS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like CNS.
CIFR PE Valuation
CIFR has no meaningful PE right now: it lost money over the past year.
CNS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 19x | $60.37 | -15% |
| Forward | 20x | $71.42 | — |
| Current | 22x | $71.42 | — |
| Fair | 25x | $80.45 | +13% |
| Expensive | 32x | $105 | +47% |
Historical ranges are pointers, not guarantees.
CNS's PE is in its fair range at 22x. If earnings grow as analysts expect, today's price would be 20x next year's earnings, in its cheap range.
CIFR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
CIFR has the edge over CNS on the outlook, with more favorable revenue expectations.
CNS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect CNS's earnings to grow and its profitability to improve, with its revenue holding steady.
CIFR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.06 | -$2.86 |
| Q2 2026 | -$2.85 | -$2.40 |
| Q1 2026 | -$2.32 | -$1.94 |
| Q4 2025 | -$2.15 | -$2.01 |
| Q3 2025 | -$0.20 | -$0.07 |
| Q2 2025 | -$0.45 | -850% |
| Q1 2025 | -$0.38 | -733% |
| Q4 2024 | -$0.14 | -$0.04 |
CIFR lost $3.06 per share over the past year, and its loss has widened in each of the last four quarters.
CNS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.64 | +12% |
| Q3 2026 | $3.25 | +1.9% |
| Q2 2026 | $3.25 | +3.2% |
| Q1 2026 | $3.02 | -1.3% |
| Q4 2025 | $2.97 | 0% |
| Q3 2025 | $3.19 | +19% |
| Q2 2025 | $3.15 | +23% |
| Q1 2025 | $3.06 | +19% |
| Q4 2024 | $2.97 | +14% |
CNS has the edge over CIFR on earnings quality, reporting a profit while its opponent remains loss making.
CIFR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $26.7M | -63% |
| Q2 2026 | $24.8M | -43% |
| Q1 2026 | $34.8M | -29% |
| Q4 2025 | $59.7M | +41% |
| Q3 2025 | $71.7M | +198% |
| Q2 2025 | $43.6M | +18% |
| Q1 2025 | $49M | +1.7% |
| Q4 2024 | $42.2M | -2.8% |
CIFR's revenue has slid since its 2025 peak: $27M last quarter, down 63% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -269% | -217 points |
| Q2 2026 | -316% | -212 points |
| Q1 2026 | -329% | -251 points |
| Q4 2025 | -503% | -544 points |
| Q3 2025 | -52% | +327 points |
| Q2 2025 | -104% | -60 points |
| Q1 2025 | -78% | -175 points |
| Q4 2024 | 40% | +4 points |
CIFR's operating margin was −269% last quarter, down 217 points from the same quarter a year ago.
CNS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $157.4M | +11% |
| Q2 2026 | $152.7M | +12% |
| Q1 2026 | $145.6M | +8.3% |
| Q4 2025 | $143.8M | +2.9% |
| Q3 2025 | $141.7M | +6.4% |
| Q2 2025 | $136.1M | +12% |
| Q1 2025 | $134.5M | +9.6% |
| Q4 2024 | $139.8M | +17% |
CNS has the edge over CIFR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -2.1 points |
| Q2 2026 | 35% | +2.7 points |
| Q1 2026 | 34% | +0.8 points |
| Q4 2025 | 28% | -7.3 points |
| Q3 2025 | 35% | +0.8 points |
| Q2 2025 | 32% | +0.3 points |
| Q1 2025 | 34% | +0.8 points |
| Q4 2024 | 35% | +3.5 points |
CNS has the edge over CIFR on profitability, with a higher operating margin.
CIFR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.7B | -$1.4B |
| Q2 2026 | -$653.8M | -$566.3M |
| Q1 2026 | -$462.5M | -$390.7M |
| Q4 2025 | -$280.3M | -$204.2M |
| Q3 2025 | -$256.2M | -$173.1M |
| Q2 2025 | -$87.5M | -$54.3M |
| Q1 2025 | -$71.8M | -$37.3M |
| Q4 2024 | -$76.1M | +$38M |
CNS has the stronger cash trend. Its trailing FCF is down 71% versus its history, compared with CIFR at down 974%.
CNS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $20M | -62% |
| Q1 2026 | -$51.4M | +$58.7M |
| Q4 2025 | $776K | -98% |
| Q3 2025 | $52.6M | +117% |
| Q2 2025 | -$69.8M | -357% |
| Q1 2025 | -$110M | -20588% |
| Q4 2024 | $33.1M | -31% |
| Q3 2024 | $24.2M | -50% |
CNS's free cash flow was $22M over the past year, against −$122M the year before. Free cash flow isn't a meaningful measure for financial services companies like CNS.
CIFR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.4% | +30.3M shares |
| 1 year | +12% | +46.5M shares |
| 3 years | +75% | +188M shares |
| 5 years | +102% | +222M shares |
CIFR has 440M diluted shares, up 12% from a year ago, despite $151M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7M |
| Q2 2026 | $45.2M |
| Q1 2026 | $3.8M |
| Q4 2025 | $82.3M |
| Q3 2025 | $3M |
| Q2 2025 | $3.2M |
| Q1 2025 | $1.1M |
| Q4 2024 | $16.9M |
CIFR spent $151M buying back its own shares over the past year, about six times what it spent the year before.
CNS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +253K shares |
| 1 year | +1.1% | +542K shares |
| 3 years | +5% | +2.5M shares |
| 5 years | +5.8% | +2.9M shares |
| Available history | +7% | +3.4M shares |
CNS has the edge over CIFR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $358,000 |
| Q2 2026 | $394,000 |
| Q1 2026 | $16.9M |
| Q4 2025 | $1.6M |
| Q3 2025 | $258,000 |
| Q2 2025 | $621,000 |
| Q1 2025 | $26M |
| Q4 2024 | $1.5M |
CNS spent $19M buying back its own shares over the past year, down 32% from the year before.
CIFR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -2.3x | Net Cash |
| Q1 2025 | 125.4x | High |
| Q4 2024 | 0.5x | Very low |
| Q3 2024 | -0.7x | Net Cash |
| Q2 2024 | -1.2x | Net Cash |
| Q1 2024 | -0.9x | Net Cash |
| Q4 2023 | -2.2x | Net Cash |
| Q2 2023 | -0.1x | Net Cash |
CIFR has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like CIFR.
CNS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | -0.8x | Net Cash |
| Q3 2025 | -0.5x | Net Cash |
| Q2 2025 | -0.5x | Net Cash |
| Q1 2025 | -0.4x | Net Cash |
| Q4 2024 | -1.0x | Net Cash |
CNS has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like CNS.
CIFR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.4 | Neutral |
| Stochastic | 7.8 | Oversold |
CIFR's weekly RSI is 34 (neutral) and its Stochastic is 8 (oversold).
CNS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.8 | Neutral |
| Stochastic | 33.9 | Neutral |
CNS's weekly RSI is 45 (neutral) and its Stochastic is 34 (neutral).
CIFR PE vs Financial Services Sector
| Metric | CIFR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
CIFR has no meaningful PE right now: it lost money over the past year.
CNS PE vs Financial Services Sector
| Metric | CNS | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 13x | 69% above |
| PE % | 33 | 63 | 30 pts below |
CNS is trading at 22x earnings, a 69% premium to the Financial Services sector's median of 13x.
CIFR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.6 | 33% below |
| 20 week MA | $15.5 | 54% below |
| 50 week MA | $17.0 | 58% below |
| 100 week MA | $12.2 | 41% below |
| 200 week MA | $7.86 | 9% below |
CIFR is in a downtrend: it's below all five of its weekly moving averages, and 9% below its 200-week average.
CNS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $71.8 | 0.5% below |
| 20 week MA | $77.0 | 7.2% below |
| 50 week MA | $71.1 | 0.4% above |
| 100 week MA | $74.1 | 3.6% below |
| 200 week MA | $73.1 | 2.3% below |
CNS has the edge over CIFR on trend strength, trading above more of its moving averages.
CIFR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.92 | $9.95 | +0.3% |
| 2021 | $9.95 | $5.21 | -48% |
| 2022 | $5.21 | $0.54 | -90% |
| 2023 | $0.54 | $4.13 | +665% |
| 2024 | $4.13 | $4.86 | +18% |
| 2025 | $4.86 | $15.2 | +213% |
| 2026 YTD | $15.2 | $7.15 | -53% |
CIFR's yearly returns have swung widely, from +665% in 2023 to −90% in 2022. It's down 53% so far in 2026.
CNS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $62.7 | $73.4 | +17% |
| 2021 | $73.4 | $90.0 | +23% |
| 2022 | $90.0 | $63.2 | -30% |
| 2023 | $63.2 | $75.7 | +20% |
| 2024 | $75.7 | $93.4 | +23% |
| 2025 | $93.4 | $64.2 | -31% |
| 2026 YTD | $64.2 | $71.4 | +11% |
CNS has the edge over CIFR on returns for 2026, with the stronger performance.